期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

重视慢性肾脏病患者的贫血管理 被引量：6

原文传递
导出
摘要 肾性贫血是慢性肾脏病（CKD）最常见的并发症之一，随着肾功能的减退，贫血的发生率逐渐升高，贫血的程度亦逐渐加重。自1989年美国食品药品管理局（FDA）批准红细胞生成刺激剂（ESA）上市以来，ESA已成为透析和非透析CKD患者贫血的常规治疗药物。ESA能通过纠正肾性贫血而延缓患者的CKD进展，减少CKD患者的心血管事件发生率，
作者 陈楠 陈晓农
机构地区 上海交通大学医学院附属瑞金医院肾脏科
出处 《中华内科杂志》 CAS CSCD 北大核心 2013年第6期447-449,共3页 Chinese Journal of Internal Medicine
关键词 美国食品药品管理局 肾性贫血 慢性肾脏病 患者 红细胞生成 心血管事件 CKD 治疗药物
分类号 R692.5 [医药卫生—泌尿科学]
  • 相关文献

参考文献11

  • 1张伟明,钱家麒.上海市透析登记及其结果分析[J].中国血液净化,2012,11(5):233-236. 被引量：86
  • 2北京市血液透析质量控制和改进中心.北京市血液透析登记2012年年度报告.中国血液净化,2012,11(增刊):32.
  • 3National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease : evaluation, classification, and stratification. Am J Kidney Dis, 2002,39(2 Suppl 1) :S1-266.
  • 4Locatelli F, Aljama P, Barany P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant, 2004,19 Suppl 2 : ii1-47.
  • 5Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Inter Suppl, 2012, 2: 279-335.
  • 6Drueke TB, Loeatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med, 2006,355:2071-2084.
  • 7Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med, 2006,355 : 2085 -2098.
  • 8Goldsmith D, Covic A. Time to Reconsider Evidence for Anaemia Treatment (TREAT) = Essential Safety Arguments (ESA). Nephrol Dial Transplant, 2010,25 : 1734-1737.
  • 9Palmer SC, Navaneethan SD, Craig JC, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intem Med, 2010,153:23-33.
  • 10Zhang W, Gong Z, Peng X, et al. Clinical characteristics and outcomes of rural patients with ESRD in Guangxi, China: one dialysis center experience. Int Urol Nephro1,2010 ,42 : 195-204.

二级参考文献21

  • 1FinkelsteinFO, Story K, Firanek C, et al.Health-related quality of life and hemoglobin levels in chronic kidney disease patients.Clin J Am Soc Nephrol, 2009,4:33-38.
  • 2PerlmanRL, Finkelstein FO, Liu L,et al.Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD study.Am J Kidney Dis, 2005,45:658-666.
  • 3WalkerAM, Schneider G, Yeaw J, et al.Anemia as a predictor of cardiovascular events in patients with elevated serum creatinine.J Am Soc Nephrol, 2006,17:2293-2298.
  • 4SilverbergD.Outcomes of anaemia management in renal insufficiency and cardiac disease.Nephrol Dial Transplant, 2003,18 Suppl 2:ii7-12.
  • 5LiS, Foley RN, Collins AJ.Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States.Kidney Int, 2004,65:1864-1869.
  • 6Regidor DL, Kopple JD, Kovesdy CP, et al.Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients.J Am Soc Nephrol, 2006,17:1181-1191.
  • 7IV.NKFK/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000.Am J Kidney Dis, 2001,37(1 Suppl 1):S182-238.
  • 8Cameron JS.European best practice guidelines for the management of anaemia in patients with chronic renal failure.Nephrol Dial Transplant, 1999,14 Suppl 2:61-65.
  • 9Macdougall IC, Robson R, Opatrna S, et al.Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease.Clin J Am Soc Nephrol, 2006,1:1211-1215.
  • 10SulowiczW, Locatelli F, Ryckelynck JP,et al.Once-monthly subcutaneous C.E.R.A.maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.Clin J Am Soc Nephrol, 2007,2:637-646.

共引文献113

同被引文献44

  • 1刘力生.中国高血压防治指南2010[J].中国医学前沿杂志（电子版）,2011,3(5):42-93. 被引量：1244
  • 2中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量：5235
  • 3陆再英,钟南山.内科学[M].第7版.北京:人民卫生出版社,2010:387-395.
  • 4Nurko S.Anemia in chronic kidney disease:causes,diagnosis,treatment[J].Clevel Clin J Med,2006;73(3):289.
  • 5Mittal SK,Ahern L,Flaster E,et al.Self-assessed physical and mental function of haemodialysis patients[J].Nephrol Dial Transplant,2001;16(7):1387-94.
  • 6National Kidney Foundation.KDOQI Clinical Practice Guideline for Diabetes and CKD:2012 Update[J].Am J Kidney Dis,2012;60(5):850-86.
  • 7Portolés J,Gorriz JL,Rubio E,et al.The development of anemia is associated to poor prognosis in NKF/KDOQI stage 3 chronic kidney disease[J].BMC Nephrol,2013;14(1):2.
  • 8Lajdova I,Spustova V,Oksa A,et al.Intracellular calcium homeostasis in patients with early stagesof chronic kidney disease:effects of vitamin D3supplementation[J].Nephrol Dial Transplant,2009;24(11):3376-81.
  • 9Bhuriya R,Li S,Chen SC,et al.Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4:an analysis from the Kidney Early Evaluation Program(KEEP)[J].Am J Kid Dis,2009;53 (4):S3-10.
  • 10Voormolen N,Noordzij M,Grootendorst DC,et al.High plasma phosphate as a risk factor for decline in renal function and mortality in predialysis patients[J].Nephrol Dial Transplant,2007;22(10):2909-16.

引证文献6

二级引证文献19

中华内科杂志
2013年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部